ATE188740T1 - Viruspartikel mit veraendertem wirtspektrum - Google Patents
Viruspartikel mit veraendertem wirtspektrumInfo
- Publication number
- ATE188740T1 ATE188740T1 AT91915104T AT91915104T ATE188740T1 AT E188740 T1 ATE188740 T1 AT E188740T1 AT 91915104 T AT91915104 T AT 91915104T AT 91915104 T AT91915104 T AT 91915104T AT E188740 T1 ATE188740 T1 AT E188740T1
- Authority
- AT
- Austria
- Prior art keywords
- methods
- altered host
- incorporation
- virus particles
- disclosed
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title abstract 4
- 239000002245 particle Substances 0.000 title abstract 2
- 238000001228 spectrum Methods 0.000 title 1
- 238000000034 method Methods 0.000 abstract 3
- 241000713869 Moloney murine leukemia virus Species 0.000 abstract 2
- 238000010348 incorporation Methods 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 239000013598 vector Substances 0.000 abstract 2
- 108091006027 G proteins Proteins 0.000 abstract 1
- 102000030782 GTP binding Human genes 0.000 abstract 1
- 108091000058 GTP-Binding Proteins 0.000 abstract 1
- 102000018697 Membrane Proteins Human genes 0.000 abstract 1
- 108010052285 Membrane Proteins Proteins 0.000 abstract 1
- 108091005461 Nucleic proteins Proteins 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000001177 retroviral effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13051—Methods of production or purification of viral material
- C12N2740/13052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13061—Methods of inactivation or attenuation
- C12N2740/13062—Methods of inactivation or attenuation by genetic engineering
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65863291A | 1991-02-19 | 1991-02-19 | |
| PCT/US1991/005699 WO1992014829A1 (en) | 1991-02-19 | 1991-08-09 | Viral particles having altered host range |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE188740T1 true ATE188740T1 (de) | 2000-01-15 |
Family
ID=24642035
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT91915104T ATE188740T1 (de) | 1991-02-19 | 1991-08-09 | Viruspartikel mit veraendertem wirtspektrum |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0572401B2 (de) |
| JP (1) | JP3547129B2 (de) |
| AT (1) | ATE188740T1 (de) |
| CA (1) | CA2104396C (de) |
| DE (1) | DE69131908T3 (de) |
| WO (1) | WO1992014829A1 (de) |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5512421A (en) * | 1991-02-19 | 1996-04-30 | The Regents Of The University Of California | Generation, concentration and efficient transfer of VSV-G pseudotyped retroviral vectors |
| EP0633943A4 (de) * | 1992-04-03 | 1997-05-02 | Alexander T Young | Gentherapy unter verwendung zielgerichteter viraler vektoren. |
| DE69333115D1 (de) * | 1992-09-22 | 2003-08-28 | Biofocus Discovery Ltd | Rekombinante viren, die an ihrer äusseren oberfläche ein nichtvirales polypeptid präsentieren |
| GB9223084D0 (en) * | 1992-11-04 | 1992-12-16 | Imp Cancer Res Tech | Compounds to target cells |
| DE69333471T2 (de) * | 1992-11-09 | 2005-02-24 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Erzielbare vektorenpartikel |
| AU7681394A (en) * | 1993-09-03 | 1995-03-22 | Chiron Viagene, Inc. | Methods of suppressing graft rejection |
| AU3635695A (en) * | 1994-09-19 | 1996-04-09 | Board Of Trustees Of The Leland Stanford Junior University | Methods for genetically modifying hematopoietic stem cells |
| US5871986A (en) | 1994-09-23 | 1999-02-16 | The General Hospital Corporation | Use of a baculovirus to express and exogenous gene in a mammalian cell |
| US5681746A (en) * | 1994-12-30 | 1997-10-28 | Chiron Viagene, Inc. | Retroviral delivery of full length factor VIII |
| US6818439B1 (en) | 1994-12-30 | 2004-11-16 | Chiron Corporation | Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders |
| US6117681A (en) * | 1995-03-29 | 2000-09-12 | Bavarian Nordic Research Inst. A/S | Pseudotyped retroviral particles |
| US5750396A (en) * | 1995-05-08 | 1998-05-12 | St. Judes Children's Research Hospital | Stable virus packaging cell lines |
| JPH11507244A (ja) * | 1995-10-05 | 1999-06-29 | カイロン コーポレイション | Ｓｒｖ−３エンベロープ糖タンパク質配列で偽型化したレトロウイルスベクター |
| US5910434A (en) | 1995-12-15 | 1999-06-08 | Systemix, Inc. | Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant |
| US6723531B2 (en) | 1996-04-05 | 2004-04-20 | The Salk Institute For Biological Studies | Method for modulating expression of exogenous genes in mammalian systems, and products related thereto |
| US5928638A (en) * | 1996-06-17 | 1999-07-27 | Systemix, Inc. | Methods for gene transfer |
| US5739018A (en) * | 1996-08-07 | 1998-04-14 | The Regents Of The University Of California | Packaging cell lines for pseudotyped retroviral vectors |
| US6133027A (en) * | 1996-08-07 | 2000-10-17 | City Of Hope | Inducible expression system |
| WO1998011243A2 (en) * | 1996-09-11 | 1998-03-19 | The General Hospital Corporation | Expression of an exogenous gene in a mammalian cell by use of a non-mammalian dna virus having an altered coat protein |
| WO1998012311A2 (en) | 1996-09-11 | 1998-03-26 | The General Hospital Corporation | Use of a non-mammalian dna virus to express an exogenous gene in a mammalian cell |
| US6183993B1 (en) | 1996-09-11 | 2001-02-06 | The General Hospital Corporation | Complement-resistant non-mammalian DNA viruses and uses thereof |
| US6818209B1 (en) | 1998-05-22 | 2004-11-16 | Oxford Biomedica (Uk) Limited | Retroviral delivery system |
| US6300488B1 (en) | 1997-07-10 | 2001-10-09 | The Salk Institute For Biological Studies | Modified lepidopteran receptors and hybrid multifunctional proteins for use in transcription and regulation of transgene expression |
| US7078483B2 (en) | 1998-04-29 | 2006-07-18 | University Of Southern California | Retroviral vectors including modified envelope escort proteins |
| US6333318B1 (en) | 1998-05-14 | 2001-12-25 | The Salk Institute For Biological Studies | Formulations useful for modulating expression of exogenous genes in mammalian systems, and products related thereto |
| DE69941049D1 (de) * | 1998-05-22 | 2009-08-13 | Oxford Biomedica Ltd | Retrovirales verabreichungssystem |
| JP2002522029A (ja) | 1998-07-27 | 2002-07-23 | ジェネンテック・インコーポレーテッド | コートタンパク質の改変によるファージ提示における改良した形質転換効率 |
| US20030035798A1 (en) | 2000-08-16 | 2003-02-20 | Fang Fang | Humanized antibodies |
| GB9907414D0 (en) | 1999-03-31 | 1999-05-26 | Cancer Res Campaign Tech | Improvements relating to prodrugs |
| US7504253B2 (en) | 1999-06-11 | 2009-03-17 | The Burnham Institute For Medical Research | Nucleic acid encoding proteins involved in protein degradation, products and methods related thereof |
| US7057015B1 (en) | 1999-10-20 | 2006-06-06 | The Salk Institute For Biological Studies | Hormone receptor functional dimers and methods of their use |
| US6864085B2 (en) | 1999-12-14 | 2005-03-08 | Novartis Ag | Bovine immunodeficiency virus (BIV) based vectors |
| WO2001068828A2 (en) | 2000-03-13 | 2001-09-20 | Engene, Inc. | Compositions and methods for regulated protein expression in gut |
| US6656718B2 (en) | 2000-07-07 | 2003-12-02 | Cancer Research Technology Limited | Modified carboxypeptidase enzymes and their use |
| IL157335A0 (en) | 2001-03-13 | 2004-02-19 | Novartis Ag | Lentiviral packaging constructs |
| CA2524619A1 (en) | 2005-11-22 | 2007-05-22 | Ottawa Health Research Institute | Novel stem cells, nucleotide sequences and proteins therefrom |
| TWI461436B (zh) | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法 |
| EP2101813B1 (de) | 2006-11-27 | 2014-04-02 | Patrys Limited | Neues glykosyliertes zielpeptid in neoplastischen zellen |
| EP2114153B1 (de) | 2007-02-06 | 2016-11-23 | Tai June Yoo | Behandlung und prävention neurodegenerativer erkrankungen mithilfe einer gentherapie |
| EP2185694A2 (de) | 2007-08-02 | 2010-05-19 | California Stem Cell, Inc. | Neuronale vorläuferzellen und verfahren zur ableitung und reinigung neuronaler vorläuferzellen aus embryonischen stammzellen |
| JP2011500036A (ja) | 2007-10-15 | 2011-01-06 | ザ ユニバーシティー オブ クイーンズランド | 構築物系およびその使用 |
| CA2704232C (en) | 2007-11-08 | 2017-05-02 | Dana-Farber Cancer Institute, Inc. | Stimulation of anti-tumor immunity using dendritic cell/tumor cell fusions and anti-cd3/cd28 |
| ES2478820T3 (es) | 2008-02-15 | 2014-07-23 | Tufts University | Tratamiento de degeneración macular |
| US8877896B2 (en) | 2008-02-15 | 2014-11-04 | Tufts University | Compositions, methods and kits for modeling, diagnosing, and treating complement disorders |
| DK2307551T3 (en) | 2008-06-18 | 2017-03-20 | Oxford Biomedica (Uk) Ltd | CLEANING RETROVIRAL VECTORS |
| US8999919B2 (en) | 2008-10-22 | 2015-04-07 | Trustees Of Dartmouth College | Compositions and methods for inhibiting the interaction between CFTR and CAL |
| US8211487B2 (en) | 2008-11-26 | 2012-07-03 | Srinivasan Damodaran | Inhibition of ice crystal growth |
| JP5748653B2 (ja) | 2009-04-10 | 2015-07-15 | 協和発酵キリン株式会社 | 抗ｔｉｍ−３抗体を用いた血液腫瘍治療法 |
| JP5694923B2 (ja) | 2009-04-27 | 2015-04-01 | 協和発酵キリン株式会社 | 血液腫瘍治療を目的とした抗ＩＬ−３Ｒα抗体 |
| WO2011060233A1 (en) | 2009-11-11 | 2011-05-19 | The Trustees Of The University Of Pennsylvania | Anti-tem1 antibodies and uses thereof |
| US9795658B2 (en) | 2010-04-20 | 2017-10-24 | Admedus Vaccines Pty Ltd | Expression system for modulating an immune response |
| CA2843684A1 (en) | 2010-08-13 | 2012-02-16 | Tufts University | Compositions, kits and methods for treatment of macular degeneration using soluble membrane-independent cd59 protein |
| JP2014528715A (ja) | 2011-09-15 | 2014-10-30 | ロサンゼルス バイオメディカル リサーチ インスティテュート アットハーバー− ユーシーエルエー メディカル センター | ＣｏｔＨを用いたムコール菌症の免疫療法および診断法 |
| US9783610B2 (en) | 2012-04-27 | 2017-10-10 | The Trustees Of The University Of Pennsylvania | Anti-tumor endothelial marker-1 (TEM1) antibody variants and uses thereof |
| US9790269B2 (en) | 2013-02-08 | 2017-10-17 | Misfolding Diagnostics, Inc. | Transthyretin antibodies and uses thereof |
| EP3004357A4 (de) | 2013-06-04 | 2017-01-11 | The Johns Hopkins University | Peg-prom-vermittelte oberflächenexpression von avidin/streptavidin |
| US10166300B2 (en) | 2013-06-04 | 2019-01-01 | Virginia Commonwealth University | Tripartite cancer theranostic nucleic acid constructs |
| EP3004153B1 (de) | 2013-06-04 | 2019-10-30 | Virginia Commonwealth University | Rekombinantes cytokin für eine krebstherapie |
| WO2014209553A1 (en) | 2013-06-04 | 2014-12-31 | Virginia Commonwealth University | Use of a truncated ccn1 promoter for cancer diagnostics, therapeutics and theranostics |
| WO2014197586A1 (en) | 2013-06-04 | 2014-12-11 | Virginia Commonwealth University | Mda-9/syntenin promoter to image and treat metastatic cancer cells |
| EP3013945B1 (de) | 2013-06-25 | 2020-05-27 | Temple University Of The Commonwealth System Of Higher Education | Aus kortikalem knochen gewonnene stammzellen |
| EP3892291A1 (de) | 2014-08-28 | 2021-10-13 | Tufts University | Zusammensetzungen, verfahren und kits zur behandlung komplementär hervorgerufener erkrankungen |
| US9901639B2 (en) | 2015-02-13 | 2018-02-27 | Temple University—Of the Commonwealth System of Higher Education | Bone marrow origin progenitor cell or endothelial progenitor cell in combination with DNMT1 gene therapy for vascular repair in metabolic disease |
| CN105372433A (zh) * | 2015-08-21 | 2016-03-02 | 深圳出入境检验检疫局动植物检验检疫技术中心 | 一种水泡性口炎病毒抗体快速检测试纸条 |
| US10149887B2 (en) | 2015-10-23 | 2018-12-11 | Canbas Co., Ltd. | Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment |
| WO2017096432A1 (en) | 2015-12-09 | 2017-06-15 | Admedus Vaccines Pty Ltd | Immunomodulating composition for treatment |
| BR112018070948A2 (pt) | 2016-04-13 | 2019-01-29 | Orimabs Ltd. | anticorpos anti-psma e utilização dos mesmos |
| EP3299460A1 (de) | 2016-09-26 | 2018-03-28 | Johann Wolfgang Goethe-Universität Frankfurt am Main | Neuartige verbindungen und verfahren zur modulation der ubiquitinierung |
| GB201710973D0 (en) | 2017-07-07 | 2017-08-23 | Avacta Life Sciences Ltd | Scaffold proteins |
| WO2019036753A1 (en) | 2017-08-22 | 2019-02-28 | Monash University | SCREENING TESTS, MODULATORS AND MODULATION OF RECEIVER ACTIVATION FOR ADVANCED GLYCATION TERMINAL PRODUCTS (RAGE) |
| WO2019157447A1 (en) | 2018-02-12 | 2019-08-15 | Trustees Of Tufts College | Cd59 for inhibiting inflammasome activation |
| EP3781130A4 (de) | 2018-04-11 | 2022-01-26 | Precision Molecular Inc. | Therapeutische konstrukte zur behandlung von krebs |
| CA3149494A1 (en) | 2019-08-12 | 2021-02-18 | Purinomia Biotech, Inc. | Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells |
| WO2021074695A1 (en) | 2019-10-16 | 2021-04-22 | Avacta Life Sciences Limited | PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES. |
| GB202101299D0 (en) | 2020-06-09 | 2021-03-17 | Avacta Life Sciences Ltd | Diagnostic polypetides and methods |
| WO2022234003A1 (en) | 2021-05-07 | 2022-11-10 | Avacta Life Sciences Limited | Cd33 binding polypeptides with stefin a protein |
| EP4413038A1 (de) | 2021-10-07 | 2024-08-14 | Avacta Life Sciences Limited | Pd-l1-bindende affimere |
| US20240409638A1 (en) | 2021-10-07 | 2024-12-12 | Avacta Life Sciences Limited | Serum half-life extended pd-l1 binding polypeptides |
| WO2023089564A1 (en) | 2021-11-19 | 2023-05-25 | Janssen Biotech, Inc. | Method of treating geographic atrophy with a gene therapy vector expressing soluble cd59 |
| IL316289A (en) | 2022-04-29 | 2024-12-01 | Purinomia Biotech Inc | Methods and compositions for treating diseases and disorders driven by eosinophils |
| WO2025074268A1 (en) | 2023-10-02 | 2025-04-10 | Janssen Biotech, Inc. | Methods for treating macular degeneration |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1310924C (en) * | 1986-04-24 | 1992-12-01 | Francis P. Mccormick | Infective drug delivery system |
| FR2619012B1 (fr) * | 1987-08-07 | 1989-12-22 | Pasteur Institut | Vaccins dont l'epitope caracteristique est incorpore dans une proteine de picornavirus, notamment de poliovirus |
| JP2755817B2 (ja) * | 1988-11-14 | 1998-05-25 | アメリカ合衆国 | パルボウイルスキャプシド |
| JPH04504361A (ja) * | 1989-04-05 | 1992-08-06 | ノバセル コーポレイション | 感染性標的化複製―欠陥ビリオン |
| JP3034025B2 (ja) * | 1989-06-01 | 2000-04-17 | アプライド・バイオテクノロジー・インコーポレーテツド | 自己アセンブルド欠損非自己増殖性ウイルス粒子 |
| WO1991002508A1 (de) * | 1989-08-21 | 1991-03-07 | Brackmann Hans Peter | Tragbare datenerfassungsvorrichtung therapierelevanter ereignisse |
| JP3203599B2 (ja) * | 1989-10-24 | 2001-08-27 | カイロン コーポレイション | 感染性タンパク質デリバリーシステム |
-
1991
- 1991-08-09 DE DE69131908T patent/DE69131908T3/de not_active Expired - Lifetime
- 1991-08-09 EP EP91915104A patent/EP0572401B2/de not_active Expired - Lifetime
- 1991-08-09 CA CA002104396A patent/CA2104396C/en not_active Expired - Lifetime
- 1991-08-09 AT AT91915104T patent/ATE188740T1/de not_active IP Right Cessation
- 1991-08-09 WO PCT/US1991/005699 patent/WO1992014829A1/en not_active Ceased
- 1991-08-09 JP JP51451891A patent/JP3547129B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE69131908D1 (de) | 2000-02-17 |
| CA2104396C (en) | 2000-10-10 |
| DE69131908T3 (de) | 2008-04-03 |
| EP0572401A1 (de) | 1993-12-08 |
| JP3547129B2 (ja) | 2004-07-28 |
| DE69131908T2 (de) | 2000-08-17 |
| EP0572401B1 (de) | 2000-01-12 |
| EP0572401B2 (de) | 2007-11-07 |
| JPH06504905A (ja) | 1994-06-09 |
| WO1992014829A1 (en) | 1992-09-03 |
| AU8430291A (en) | 1992-09-15 |
| CA2104396A1 (en) | 1992-08-20 |
| AU663470B2 (en) | 1995-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE188740T1 (de) | Viruspartikel mit veraendertem wirtspektrum | |
| NO871785D0 (no) | Fremgangsmaate for fremstilling av et proteinprodukt, samt vektorsystem for fremgangsmaatens utfoerelse. | |
| IL89701A0 (en) | Recombinant retroviruses,method for the production thereof and pharmaceutical composition containing the same | |
| DE69636878D1 (de) | Zirkuläres DNA Molekül mit einem abhängigen Replikationsursprung, seine Herstellungsverfahren und seine Verwendung in der Gentherapie | |
| DK0561890T3 (da) | DNA ekspressionssystemer baseret på alphavira | |
| WO1991002805A3 (en) | Recombinant retroviruses delivering vector constructs to target cells | |
| ATE114476T1 (de) | Tierische zelle mit darin eingeführtem antigenem protein. | |
| DE69434820D1 (de) | Nukleinsäurevektor, einen solchen vektor enthaltene verbindung und impfstoff zur immunisierung gegen hepatitis | |
| AU1138388A (en) | Hybrid rna virus | |
| ATE316571T1 (de) | Purifikation von viruspräparaten | |
| DE69921435D1 (de) | Verfahren zur Inaktivierung vom umhüllten Viren in einem Viruspräparat mit Adenoviren | |
| ATE101200T1 (de) | Impfstoffe gegen menschliche respiratorische viren. | |
| WO1994013812A3 (en) | Novel entomopoxvirus genes, proteins and methods of use thereof | |
| EP0676413A3 (de) | Interferon alpha/beta bindendes Protein, seine Herstellung und Anwendung. | |
| EP0836484A4 (de) | In-vitro verpackung von adeno-assozierten virus dns | |
| Will et al. | Hepatitis B after infection of a chimpanzee with cloned HBV DNA | |
| JPS5545618A (en) | Thermal treatment of fraction containing glycoprotein which accelerates differentiation and proliferation of human granulocyte | |
| ES2175184T3 (es) | Virus que expresan proteinas toxicas y leneas celulares productoras. | |
| Bosworth et al. | Evaluation of age-related effects on the antiviral activity of interferon and induction of 2-5A synthetase in testicular cell cultures derived from swine of various ages | |
| EP0460217A4 (en) | Cdna of orsv gene | |
| Macaulay | Regulation of gene expression in Shope fibroma virus | |
| ATE52798T1 (de) | Hepatitis-b-virus-gen enthaltendes rekombinantes plasmid, mit diesem rekombinanten plasmid transformierte hefe und herstellung von hepatitis-b-virus-oberflaechenantigen. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |